Study: Lynparza can reduce relapse, death in some breast cancer patients


In a study published last week in The New England Journal of Medicine, British drugmaker AstraZeneca said that in a late-stage trial, its drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain gene mutations.
Lynparza was developed with Merck, and works to inhibit PARP, a protein that repairs DNA damage to cells — including those that are cancerous. It can be given as a maintenance therapy or an active treatment after chemotherapy. The study found that compared to a placebo, Lynparza reduced the combined risk of recurrence of breast cancer or death from any cause by 42 percent, Reuters reports.
Globally, breast cancer is now the most common form of the disease, the World Health Organization said in February, accounting for almost 12 percent of new cases every year.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Thai fish pie with crispy turmeric potatoes recipe
The Week Recommends Tasty twist on the Lancashire hot pot is given a golden glow
-
Palestine Action: protesters or terrorists?
Talking Point Damaging RAF equipment at Brize Norton blurs line between activism and sabotage, but proscription is a drastic step
-
Trump's strikes on Iran: a 'spectacular success'?
In Depth Military humiliations 'expose the brittleness' of Tehran's ageing regime, but risk reinforcing its commitment to its nuclear program
-
New York plans first nuclear plant in 36 years
Speed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes
-
A potentially mutating bat virus has some scientists worried about the next pandemic
Under the Radar One subgroup of bat merbecovirus has scientists concerned
-
Dehorning rhinos sharply cuts poaching, study finds
Speed Read The painless procedure may be an effective way to reduce the widespread poaching of rhinoceroses
-
Breakthrough gene-editing treatment saves baby
speed read KJ Muldoon was healed from a rare genetic condition
-
Sea lion proves animals can keep a beat
speed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study
-
Humans heal much slower than other mammals
Speed Read Slower healing may have been an evolutionary trade-off when we shed fur for sweat glands
-
Novel 'bone collector' caterpillar wears its prey
Speed Read Hawaiian scientists discover a carnivorous caterpillar that decorates its shell with the body parts of dead insects
-
Scientists find hint of alien life on distant world
Speed Read NASA's James Webb Space Telescope has detected a possible signature of life on planet K2-18b